Persistent IL ‐18 fuels expansion of CD38 + HLA ‐ DR + CD8 + T cells in Still's disease and macrophage activation syndrome

Objective Still's disease (SD) is an autoinflammatory disorder characterized by remarkably high IL‐18 levels. Increasing evidence suggests that adaptive immunity also contributes to its pathogenesis, particularly in refractory courses. Macrophage activation syndrome (MAS), one of SD's most severe complications, is associated with further IL‐18 elevation and expansion of CD38 + HLA‐DR + CD8 + T cells. However, whether and when this population emerges during SD remains unknown. We therefore examined CD38 + HLA‐DR + CD8 + T cells across disease stages. Methods CD38 + HLA‐DR + CD8 + T cells were analyzed longitudinally: at SD‐onset (therapy‐naïve; n=19), during clinically inactive disease (n=15), and prior to or at MAS occurrence (n=12). Spectral flow cytometry and bulk RNA‐sequencing were performed. Correlations with clinical and laboratory parameters were assessed. In vitro cytokine stimulations of healthy donor (HD)‐derived PBMCs and CD8 + lymphocytes were performed to explore mechanisms driving differentiation of these cells. Results CD38 + HLA‐DR + CD8 + T cells were expanded from SD‐onset and peaked in MAS (median: 4.61% and 31.7%, respectively, versus 0.87% in HD). Transcriptomic profiling of these cells revealed enrichment of activation, cytotoxicity, and proliferation programs, which were confirmed at the protein level. Frequencies correlated with markers of systemic inflammation, T‐cell activation, and serum IL‐18 levels. Sustained IL‐18 stimulation in vitro induced robust and persistent expansion of CD38 + HLA‐DR + CD8 + cells, recapitulating key ex vivo phenotypic features. Conclusion CD38 + HLA‐DR + CD8 + cells, previously primarily associated with MAS, are detectable early in SD. Persistent IL‐18 exposure promotes their expansion. These findings identify CD38 + HLA‐DR + CD8 + T cells as a potential mechanistic link between SD and MAS and highlight this subset as a candidate therapeutic target. image

Authors

Institutions

Publication Details

Journal
Arthritis & Rheumatology
Published
2026-09-01
DOI
https://doi.org/10.1002/art.70319
Primary Topic
Autoimmune and Inflammatory Disorders Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Persistent IL ‐18 fuels expansion of CD38 + HLA ‐ DR + CD8 + T cells in Still's disease and macrophage activation syndrome

Francesca Minoia, Freya M. C. H. Huijsmans, Noël M M Dautzenberg, Joyce I. Meesters-Ensing et al.
Arthritis & Rheumatology
Autoimmune and Inflammatory Disorders Research
article

Persistent IL ‐18 fuels expansion of CD38 + HLA ‐ DR + CD8 + T cells in Still's disease and macrophage activation syndrome

Francesca Minoia, Freya M. C. H. Huijsmans, Noël M M Dautzenberg, Joyce I. Meesters-Ensing, Laura Porretti, Jorg van Loosdregt, Alejandra Bodelόn, Greta Rogani, Remco G. A. Erkens, Stefan Nierkens, Lyanne J. P. M. Sijbers, Maurice J. H. van Haaren, Rianne C. Scholman, Aafke M. de Ligt, Marein T.M. Putmans, Sebastian J. Vastert, Martina Rossano, Tim R. Mocking
article en

Abstract

Objective Still's disease (SD) is an autoinflammatory disorder characterized by remarkably high IL‐18 levels. Increasing evidence suggests that adaptive immunity also contributes to its pathogenesis, particularly in refractory courses. Macrophage activation syndrome (MAS), one of SD's most severe complications, is associated with further IL‐18 elevation and expansion of CD38 + HLA‐DR + CD8 + T cells. However, whether and when this population emerges during SD remains unknown. We therefore examined CD38 + HLA‐DR + CD8 + T cells across disease stages. Methods CD38 + HLA‐DR + CD8 + T cells were analyzed longitudinally: at SD‐onset (therapy‐naïve; n=19), during clinically inactive disease (n=15), and prior to or at MAS occurrence (n=12). Spectral flow cytometry and bulk RNA‐sequencing were performed. Correlations with clinical and laboratory parameters were assessed. In vitro cytokine stimulations of healthy donor (HD)‐derived PBMCs and CD8 + lymphocytes were performed to explore mechanisms driving differentiation of these cells. Results CD38 + HLA‐DR + CD8 + T cells were expanded from SD‐onset and peaked in MAS (median: 4.61% and 31.7%, respectively, versus 0.87% in HD). Transcriptomic profiling of these cells revealed enrichment of activation, cytotoxicity, and proliferation programs, which were confirmed at the protein level. Frequencies correlated with markers of systemic inflammation, T‐cell activation, and serum IL‐18 levels. Sustained IL‐18 stimulation in vitro induced robust and persistent expansion of CD38 + HLA‐DR + CD8 + cells, recapitulating key ex vivo phenotypic features. Conclusion CD38 + HLA‐DR + CD8 + cells, previously primarily associated with MAS, are detectable early in SD. Persistent IL‐18 exposure promotes their expansion. These findings identify CD38 + HLA‐DR + CD8 + T cells as a potential mechanistic link between SD and MAS and highlight this subset as a candidate therapeutic target. image

Arthritis & Rheumatology
Utrecht University (NL), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University Medical Center Utrecht (NL), Princess Máxima Center (NL), Wilhelmina Children's Hospital (NL)
Dutch Arthritis Society, Arthritis Society, ZonMw, Swedish Orphan Biovitrum
Openalex Percentile: Top 11%
Autoimmune and Inflammatory Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.